{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:04:48Z","timestamp":1793466288478,"version":"4.5.0"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-024-01492-8","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T09:01:41Z","timestamp":1737018101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug delivery strategies for the treatment of relapse behavior in substance use disorder- A systematic review"],"prefix":"10.1007","volume":"40","author":[{"given":"Megha","family":"Sihag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"2","key":"1492_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.amepre.2008.04.009","volume":"35","author":"A Clinical Practice Guideline for Treating Tobacco Use and Dependence","year":"2008","unstructured":"A Clinical Practice Guideline for Treating Tobacco Use and Dependence (2008) 2008 Update. A U.S. Public Health Service Report. Am J Prev Med 35(2):158\u2013176. https:\/\/doi.org\/10.1016\/j.amepre.2008.04.009","journal-title":"Am J Prev Med"},{"issue":"24","key":"1492_CR2","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1001\/JAMA.2020.6647","volume":"323","author":"JM Adams","year":"2020","unstructured":"Adams JM (2020) Smoking Cessation\u2014Progress, barriers, and New opportunities: the Surgeon General\u2019s Report on Smoking Cessation. JAMA 323(24):2470\u20132471. https:\/\/doi.org\/10.1001\/JAMA.2020.6647","journal-title":"JAMA"},{"key":"1492_CR3","doi-asserted-by":"publisher","unstructured":"Akkus F, Mihov Y, Treyer V, Ametamey SM, Johayem A, Senn S, R\u00f6sner S, Buck A, Hasler G (2018) Metabotropic glutamate receptor 5 binding in male patients with alcohol use disorder. Translational Psychiatry 2017 8:1(1):1\u20138. https:\/\/doi.org\/10.1038\/s41398-017-0066-6","DOI":"10.1038\/s41398-017-0066-6"},{"key":"1492_CR4","doi-asserted-by":"publisher","first-page":"101363","DOI":"10.1016\/j.pmedr.2021.101363","volume":"22","author":"M Al-Hamdani","year":"2021","unstructured":"Al-Hamdani M, Manly E (2021) Smoking cessation or initiation: the paradox of vaping. Prev Med Rep 22:101363. https:\/\/doi.org\/10.1016\/j.pmedr.2021.101363","journal-title":"Prev Med Rep"},{"key":"1492_CR5","unstructured":"American Lung Association (2024) Health effects of secondhand smoke.\u00a0Retrieved from: https:\/\/www.lung.org\/quit-smoking\/smoking-facts\/health-effects\/secondhand-smoke.\u00a0Accessed 24 Dec 2024"},{"issue":"7","key":"1492_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMct0801733","volume":"359","author":"RF Anton","year":"2008","unstructured":"Anton RF (2008) Naltrexone for the management of alcohol dependence. N Engl J Med 359(7):715\u2013721. https:\/\/doi.org\/10.1056\/NEJMct0801733","journal-title":"N Engl J Med"},{"issue":"16","key":"1492_CR7","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1016\/J.VACCINE.2006.01.047","volume":"24","author":"B Anton","year":"2006","unstructured":"Anton B, Leff P (2006) A novel bivalent morphine\/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24(16):3232\u20133240. https:\/\/doi.org\/10.1016\/J.VACCINE.2006.01.047","journal-title":"Vaccine"},{"issue":"17","key":"1492_CR8","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/JAMA.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295(17):2003\u20132017. https:\/\/doi.org\/10.1001\/JAMA.295.17.2003","journal-title":"JAMA"},{"issue":"2","key":"1492_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/BCP.12116","volume":"77","author":"HJ Aubin","year":"2014","unstructured":"Aubin HJ, Luquiens A, Berlin I (2014) Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol 77(2):324\u2013336. https:\/\/doi.org\/10.1111\/BCP.12116","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1492_CR10","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1038\/sj.npp.1300274","volume":"28","author":"RT Bartus","year":"2003","unstructured":"Bartus RT, Emerich DF, Hotz J, Blaustein M, Dean RL, Perdomo B, Basile AS (2003) Vivitrex\u00ae, an Injectable, extended-release formulation of Naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for I Month in rats. Neuropsychopharmacology 28(11):1973\u20131982. https:\/\/doi.org\/10.1038\/sj.npp.1300274","journal-title":"Neuropsychopharmacology"},{"issue":"4067","key":"1492_CR11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1126\/SCIENCE.178.4067.1290","volume":"178","author":"B Berkowitz","year":"1972","unstructured":"Berkowitz B, Spector S (1972) Evidence for active immunity to Morphine in mice. Science 178(4067):1290\u20131292. https:\/\/doi.org\/10.1126\/SCIENCE.178.4067.1290","journal-title":"Science"},{"key":"1492_CR12","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41386-021-01097-0","volume":"46","author":"JM Biernacka","year":"2021","unstructured":"Biernacka JM, Coombes BJ, Batzler A, Ho AMC, Geske JR, Frank J, Hodgkinson C, Skime M, Zillich L, Pozsonyiova S, Ho MF, Kiefer F, Rietschel M, Weinshilboum R, O\u2019Malley SS, Mann K, Anton R, Goldman D, Karpyak VM (2021) Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacol 46:2132\u20132139. https:\/\/doi.org\/10.1038\/s41386-021-01097-0","journal-title":"Neuropsychopharmacol"},{"key":"1492_CR13","doi-asserted-by":"publisher","unstructured":"Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR (1974) Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974\u00a0252(5485):708\u2013710. https:\/\/doi.org\/10.1038\/252708a0","DOI":"10.1038\/252708a0"},{"issue":"1","key":"1492_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1471-4159.1993.tb05820.x","volume":"60","author":"DM Bronstein","year":"1993","unstructured":"Bronstein DM, Day NC, Gutstein HB, Trujillo KA, Akil H (1993) Pre- and posttranslational regulation of \u03b2\u2010Endorphin biosynthesis in the CNS: effects of Chronic Naltrexone Treatment. J Neurochem 60(1):40\u201349. https:\/\/doi.org\/10.1111\/j.1471-4159.1993.tb05820.x","journal-title":"J Neurochem"},{"key":"1492_CR15","doi-asserted-by":"publisher","unstructured":"Castaldelli-Maia JM, Bhugra D (2022) Analysis of global prevalence of mental and substance use disorders within countries: focus on sociodemographic characteristics and income levels. Int Rev Psychiatry\u00a034(1):6\u201315. https:\/\/doi.org\/10.1080\/09540261.2022.2040450","DOI":"10.1080\/09540261.2022.2040450"},{"key":"1492_CR16","unstructured":"Centers for Disease Control (2020) Smoking cessation: a report of the surgeon general. https:\/\/www.cdc.gov\/tobacco-surgeon-general-reports\/reports\/2020-smokingcessation\/index.html. Accessed 28 Oct 2024"},{"key":"1492_CR17","unstructured":"Center for Substance Abuse Treatment (2009) Substance abuse treatment: addressing the specific needs of women. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK83252\/. Accessed 24 Dec 2024"},{"issue":"4","key":"1492_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1037\/0022-006X.72.4.712","volume":"72","author":"A Cepeda-Benito","year":"2004","unstructured":"Cepeda-Benito A, Reynoso JT, Erath S (2004) Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol 72(4):712\u2013722. https:\/\/doi.org\/10.1037\/0022-006X.72.4.712","journal-title":"J Consult Clin Psychol"},{"key":"1492_CR19","unstructured":"Chapter 2\u2014Acamprosate - Incorporating Alcohol Pharmacotherapies Into Medical Practice - NCBI Bookshelf\u00a0(2009). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64035\/.\u00a0Accessed 23 Dec 2024"},{"issue":"5","key":"1492_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/CLPT.1984.243","volume":"36","author":"CN Chiang","year":"1984","unstructured":"Chiang CN, Hollister LE, Kishimoto A, Barnett G (1984) Kinetics of a naltrexone sustained-release preparation. Clin Pharmacol Ther 36(5):704\u2013708. https:\/\/doi.org\/10.1038\/CLPT.1984.243","journal-title":"Clin Pharmacol Ther"},{"key":"1492_CR21","doi-asserted-by":"publisher","unstructured":"Chukwueke CC, Le Foll B (2019) The human laboratory and drug development in alcohol use disorder: recent updates. Methods Mol Biol 2011:195\u2013219. https:\/\/doi.org\/10.1007\/978-1-4939-9554-7_12","DOI":"10.1007\/978-1-4939-9554-7_12"},{"key":"1492_CR22","doi-asserted-by":"publisher","unstructured":"Ciwun M, Tankiewicz-Kwedlo A, Pawlak D (2024) Low-dose naltrexone as an adjuvant in combined anticancer therapy. Cancers (Basel) 16(6):1240. https:\/\/doi.org\/10.3390\/cancers16061240","DOI":"10.3390\/cancers16061240"},{"issue":"10","key":"1492_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","volume":"63","author":"SD Comer","year":"2006","unstructured":"Comer SD, Sullivan MA, Yu E et al (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63(10):210\u2013218. https:\/\/doi.org\/10.1001\/archpsyc.63.2.210","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"1492_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/HRP.0000000000000271","volume":"28","author":"HS Connery","year":"2020","unstructured":"Connery HS, McHugh RK, Reilly M, Shin S, Greenfield SF (2020) Substance use disorders in global mental health delivery: epidemiology, treatment gap, and implementation of evidence-based treatments. Harv Rev Psychiatry 28(5):316\u2013327. https:\/\/doi.org\/10.1097\/HRP.0000000000000271","journal-title":"Harv Rev Psychiatry"},{"issue":"1\u20132","key":"1492_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/J.BBR.2003.09.025","volume":"146","author":"E Coutureau","year":"2003","unstructured":"Coutureau E, Killcross S (2003) Inactivation of the infralimbic prefrontal cortex reinstates goal-directed responding in overtrained rats. Behav Brain Res 146(1\u20132):167\u2013174. https:\/\/doi.org\/10.1016\/J.BBR.2003.09.025","journal-title":"Behav Brain Res"},{"key":"1492_CR26","doi-asserted-by":"crossref","unstructured":"Cruciani RA, Knotkova H (eds) (2013) Handbook of methadone prescribing and buprenorphine therapy. Springer, New York","DOI":"10.1007\/978-1-4614-6974-2"},{"key":"1492_CR27","unstructured":"Davidson J (1979) Seizures and bupropion: a review.\u00a0J Clin Psychiatry\u00a050(7):256\u2013261"},{"issue":"7","key":"1492_CR28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/J.NEUBIOREV.2004.09.006","volume":"28","author":"JW Dalley","year":"2004","unstructured":"Dalley JW, Cardinal RN, Robbins TW (2004) Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28(7):771\u2013784. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2004.09.006","journal-title":"Neurosci Biobehav Rev"},{"key":"1492_CR29","doi-asserted-by":"crossref","unstructured":"Dean RL (2009) Nonclinical Pharmacology of VIVITROL\u00ae: a monthly injectable for the treatment of alcohol dependence. Opiate receptors and antagonists, Chap. 35. Humana Press","DOI":"10.1007\/978-1-59745-197-0_35"},{"key":"1492_CR30","unstructured":"Dixon DW, Pierson RP (2023) Opioid abuse: practice essentials, background, pathophysiology. Medscape. Chief Editor: Xiong GL. https:\/\/emedicine.medscape.com\/article\/287790-overview#a5.\u00a0Accessed 26 Dec 2024"},{"key":"1492_CR31","doi-asserted-by":"publisher","unstructured":"Domingo-Rodriguez L, Ruiz de Azua I, Dominguez E, Senabre E, Serra I, Kummer S, Navandar M, Baddenhausen S, Hofmann C, Andero R, Gerber S, Navarrete M, Dierssen M, Lutz B, Mart\u00edn-Garc\u00eda E, Maldonado R (2020) A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction. Nat Commun 11(1):782. https:\/\/doi.org\/10.1038\/s41467-020-14458-y","DOI":"10.1038\/s41467-020-14458-y"},{"key":"1492_CR32","doi-asserted-by":"publisher","unstructured":"Douaihy AB, Kelly TM, Sullivan C (2013) Medications for substance use disorders. Soc Work Public Health\u00a028(3\u20134):264\u2013278. https:\/\/doi.org\/10.1080\/19371918.2013.759031","DOI":"10.1080\/19371918.2013.759031"},{"key":"1492_CR33","unstructured":"Dydyk AM, Jain NK, Gupta M (2020) Opioid use disorder. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"issue":"11","key":"1492_CR34","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/nn1579","volume":"8","author":"BJ Everitt","year":"2005","unstructured":"Everitt BJ, Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8(11):1481\u20131489. https:\/\/doi.org\/10.1038\/nn1579","journal-title":"Nat Neurosci"},{"key":"1492_CR35","doi-asserted-by":"publisher","unstructured":"Faessel H, Ravva P, Williams K (2009) Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 31(1):177\u2013189. https:\/\/doi.org\/10.1016\/j.clinthera.2009.01.003","DOI":"10.1016\/j.clinthera.2009.01.003"},{"issue":"3","key":"1492_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0095-4543(05)70122-6","volume":"26","author":"LH Ferry","year":"1999","unstructured":"Ferry LH (1999) Non-nicotine pharmacotherapy for smoking cessation. Prim Care 26(3):653\u2013669. https:\/\/doi.org\/10.1016\/S0095-4543(05)70122-6","journal-title":"Prim Care"},{"issue":"2","key":"1492_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/J.1360-0443.2006.01321.X","volume":"101","author":"G Fischer","year":"2006","unstructured":"Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, Aschauer H (2006) Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction (Abingdon England) 101(2):275\u2013281. https:\/\/doi.org\/10.1111\/J.1360-0443.2006.01321.X","journal-title":"Addiction (Abingdon England)"},{"key":"1492_CR38","unstructured":"Food and Drug Administration (2008) Vivitrol intramuscular: Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021897s015lbl.pdf. Accessed 6 Oct October"},{"key":"1492_CR39","unstructured":"Food and Drug Administration (2016) Chantix (varenicline) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/. Accessed 23 Dec 2024"},{"key":"1492_CR40","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1001\/jama.1989.03430210053029","volume":"262","author":"P Franks","year":"1989","unstructured":"Franks P, Harp J, Bell B (1989) Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. JAMA 262:3011\u20133013","journal-title":"JAMA"},{"key":"1492_CR41","doi-asserted-by":"publisher","unstructured":"Giulietti F, Filipponi A, Rosettani G, Giordano P, Iacoacci C, Spannella F, Sarzani R (2020) Pharmacological approach to smoking cessation: an updated review for daily clinical practice. High Blood Press Cardiovasc Prev 27(5):349\u2013362.\u00a0Adis.\u00a0https:\/\/doi.org\/10.1007\/s40292-020-00396-9","DOI":"10.1007\/s40292-020-00396-9"},{"key":"1492_CR42","first-page":"CD000058","volume":"3","author":"SG Gourlay","year":"2004","unstructured":"Gourlay SG, Stead LF, Benowitz NL (2004) Clonidine for smoking cessation. Cochrane Database Syst Rev 3:CD000058","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1492_CR43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, Hasin DS (2015) Epidemiology of DSM-5 Alcohol Use Disorder: results from the national epidemiologic survey on Alcohol and related conditions. JAMA Psychiatry 72(8):757\u2013766. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0584","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"1492_CR44","doi-asserted-by":"publisher","first-page":"CD000546","DOI":"10.1002\/14651858.CD000546.pub2","volume":"2001","author":"P Hajek","year":"2004","unstructured":"Hajek P, Stead LF (2004) Aversive smoking for smoking cessation. Cochrane Database Syst Rev 2001(3):CD000546. https:\/\/doi.org\/10.1002\/14651858.CD000546.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1492_CR45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.7326\/0003-4819-135-6-200109180-00011","volume":"135","author":"JT Hays","year":"2001","unstructured":"Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DPL, Wolter TD, Buist AS, Johnston JA, White JD (2001) Article sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. J Am Med Association 135:423\u2013434. https:\/\/doi.org\/10.7326\/0003-4819-135-6-200109180-00011","journal-title":"J Am Med Association"},{"issue":"1","key":"1492_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4103\/0253-7176.112194","volume":"35","author":"A Hegde","year":"2013","unstructured":"Hegde A, Singh SM, Sarkar S (2013) Long-acting preparations in substance abuse management: a review and update. Indian J Psychol Med 35(1):10\u201318. https:\/\/doi.org\/10.4103\/0253-7176.112194","journal-title":"Indian J Psychol Med"},{"issue":"6","key":"1492_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/J.NEUBIOREV.2003.09.003","volume":"27","author":"CA Heidbreder","year":"2003","unstructured":"Heidbreder CA, Groenewegen HJ (2003) The medial prefrontal cortex in the rat: evidence for a dorso-ventral distinction based upon functional and anatomical characteristics. Neurosci Biobehavioral Reviews 27(6):555\u2013579. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2003.09.003","journal-title":"Neurosci Biobehavioral Reviews"},{"issue":"5","key":"1492_CR48","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3322\/CANJCLIN.55.5.281","volume":"55","author":"JE Henningfield","year":"2005","unstructured":"Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML (2005) Pharmacotherapy for nicotine dependence. Cancer J Clin 55(5):281\u2013299. https:\/\/doi.org\/10.3322\/CANJCLIN.55.5.281","journal-title":"Cancer J Clin"},{"key":"1492_CR49","unstructured":"Huecker MR, Smiley A, Saadabadi A (2022) Bupropion In: StatPearls. Treasure Island (FL): StatPearls Publishing"},{"key":"1492_CR50","doi-asserted-by":"publisher","unstructured":"Hughes JR, Peters EN, Callas PW, Peasley-Miklus C, Oga E, Etter JF, Morley N (2020) Withdrawal symptoms from E-Cigarette abstinence among former smokers: a pre-post clinical trial. Nicotine Tob Research: Official J Soc Res Nicotine Tob 22(5):734\u2013739. https:\/\/doi.org\/10.1093\/ntr\/ntz129","DOI":"10.1093\/ntr\/ntz129"},{"issue":"10","key":"1492_CR51","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/ARCHGENPSYCHIATRY.2009.130","volume":"66","author":"GK Hulse","year":"2009","unstructured":"Hulse GK, Morris N, Arnold-Reed D, Tait RJ (2009) Improving clinical outcomes in treating Heroin Dependence: Randomized, controlled trial of oral or Implant Naltrexone. Arch Gen Psychiatry 66(10):1108\u20131115. https:\/\/doi.org\/10.1001\/ARCHGENPSYCHIATRY.2009.130","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1492_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/S002130050744","volume":"140","author":"RD Hurt","year":"1998","unstructured":"Hurt RD, Offord KP, Croghan IT, Croghan GA, Gomez-Dahl LC, Wolter TD, Dale LC, Moyer TP (1998) Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology 140(1):98\u2013104. https:\/\/doi.org\/10.1007\/S002130050744","journal-title":"Psychopharmacology"},{"key":"1492_CR53","unstructured":"Injectable fomulations of disulfiram for the treatment of alcoholism (1985) Chem Absts\u00a086:172533. Accessed from: https:\/\/patents.google.com\/patent\/US4678809A\/en"},{"issue":"7","key":"1492_CR54","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/add.15403","volume":"116","author":"SE Jackson","year":"2021","unstructured":"Jackson SE, Brown J, Jarvis MJ (2021) Dependence on nicotine in US high school students in the context of changing patterns of tobacco product use. Addiction 116(7):1859\u20131870. https:\/\/doi.org\/10.1111\/add.15403","journal-title":"Addiction"},{"key":"1492_CR55","doi-asserted-by":"publisher","unstructured":"Jarvis MJ, Jackson SE, Brown J (2020) Epidemic of youth nicotine addiction? What does the National Youth Tobacco Survey 2017\u20132019 reveal about high school e-cigarette use in the USA? Qeios. https:\/\/doi.org\/10.32388\/745076.5","DOI":"10.32388\/745076.5"},{"issue":"5","key":"1492_CR56","first-page":"741","volume":"3","author":"BA Johnson","year":"2007","unstructured":"Johnson BA (2007) Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manag 3(5):741. \/pmc\/articles\/PMC2376083\/","journal-title":"Ther Clin Risk Manag"},{"key":"1492_CR57","doi-asserted-by":"crossref","unstructured":"Johnston LD, Miech RA, O\u2019Malley PM, Bachman JG, Schulenberg JE, Patrick ME (2018) Monitoring the future national survey results on drug use, 1975\u20132017: overview, key findings on adolescent drug use. Institute for Social Research, University of Michigan. Retrieved from: https:\/\/eric.ed.gov\/?id=ED594190.\u00a0Accessed 28 Oct 2024","DOI":"10.3998\/2027.42\/148123"},{"issue":"18","key":"1492_CR58","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/JAMA.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC (2014) Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 311(18):1889\u20131900. https:\/\/doi.org\/10.1001\/JAMA.2014.3628","journal-title":"JAMA"},{"key":"1492_CR59","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen CH, Pedersen B, T\u00f8nnesen H (2011) The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 35(10):1749\u20131758. https:\/\/doi.org\/10.1111\/j.1530-0277.2011.01523.x","DOI":"10.1111\/j.1530-0277.2011.01523.x"},{"key":"1492_CR60","doi-asserted-by":"publisher","first-page":"121275","DOI":"10.1016\/J.IJPHARM.2021.121275","volume":"611","author":"H Kamali","year":"2022","unstructured":"Kamali H, Karimi M, Abbaspour M, Nadim A, Hadizadeh F, Khodaverdi E, Eisvand F (2022) Comparison of lipid liquid crystal formulation and Vivitrol\u00ae for sustained release of Naltrexone: in vitro evaluation and pharmacokinetics in rats. Int J Pharm 611:121275. https:\/\/doi.org\/10.1016\/J.IJPHARM.2021.121275","journal-title":"Int J Pharm"},{"key":"1492_CR61","doi-asserted-by":"publisher","unstructured":"Kann L, McManus T, Harris WA, Shanklin SL, Flint KH, Hawkins J, Queen B, Lowry R, Olsen EOM, Chyen D, Whittle L, Thornton J, Lim C, Yamakawa Y, Brener N, Zaza S (2020) Youth risk behavior surveillance \u2014 United States, 2015. MMWR Surveill Summ\u00a065(6):1\u2013180. https:\/\/doi.org\/10.15585\/MMWR.SS6506A1","DOI":"10.15585\/MMWR.SS6506A1"},{"issue":"2","key":"1492_CR62","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/02791072.2022.2073300","volume":"55","author":"SK Kedia","year":"2023","unstructured":"Kedia SK, Ahuja N, Dillon PJ, Jones A, Kumar S, Satapathy S (2023) Efficacy of extended-release Injectable Naltrexone on Alcohol Use Disorder treatment: a systematic review. J Psychoactive Drugs 55(2):233\u2013245. https:\/\/doi.org\/10.1080\/02791072.2022.2073300","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"1492_CR63","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","volume":"161","author":"S Kempe","year":"2012","unstructured":"Kempe S, M\u00e4der K (2012) In situ forming implants \u2014 an attractive formulation principle for parenteral depot formulations. J Controlled Release 161(2):668\u2013679. https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.016","journal-title":"J Controlled Release"},{"issue":"12","key":"1492_CR64","first-page":"3436","volume":"33","author":"H Kimura","year":"1992","unstructured":"Kimura H, Ogura Y, Moritera T, Honda Y, Wada R, Hyon SH, Ikada Y (1992) Injectable microspheres with controlled drug release for glaucoma filtering surgery. Invest Opthalmology Visual Sci 33(12):3436\u20133441","journal-title":"Invest Opthalmology Visual Sci"},{"issue":"2","key":"1492_CR65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/jps.21463","volume":"98","author":"PK Kiptoo","year":"2010","unstructured":"Kiptoo PK, Paudel KS, Hammell DC, Pinninti RR, Chen J, Crooks PA, Stinchcomb A (2010) Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach. J Pharm Sci 98(2):583\u2013594. https:\/\/doi.org\/10.1002\/jps.21463","journal-title":"J Pharm Sci"},{"issue":"4","key":"1492_CR66","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/J.MCNA.2016.03.011","volume":"100","author":"JW Klein","year":"2016","unstructured":"Klein JW (2016) Pharmacotherapy for Substance Use disorders. Med Clin North Am 100(4):891\u2013910. https:\/\/doi.org\/10.1016\/J.MCNA.2016.03.011","journal-title":"Med Clin North Am"},{"issue":"3","key":"1492_CR67","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1211\/jpp.58.3.0002","volume":"58","author":"SR Kleppner","year":"2010","unstructured":"Kleppner SR, Patel R, Costantini LC, McDonough J (2010) In-vitro and in-vivo characterization of a buprenorphine delivery system. J Pharm Pharmacol 58(3):295\u2013302. https:\/\/doi.org\/10.1211\/jpp.58.3.0002","journal-title":"J Pharm Pharmacol"},{"key":"1492_CR68","doi-asserted-by":"publisher","unstructured":"Koob GF, Volkow ND (2009) Neurocircuitry of addiction. Neuropsychopharmacology 2010 35(1):217\u2013238. https:\/\/doi.org\/10.1038\/npp.2009.110","DOI":"10.1038\/npp.2009.110"},{"issue":"8","key":"1492_CR69","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3(8):760\u2013773. https:\/\/doi.org\/10.1016\/S2215-0366(16)00104-8","journal-title":"Lancet Psychiatry"},{"key":"1492_CR70","doi-asserted-by":"publisher","unstructured":"Koob GF, Arends MA, Le Moal M (2014) Drugs, addiction, and the brain. Drugs Addict Brain 1\u2013342. https:\/\/doi.org\/10.1016\/C2010-0-68399-4","DOI":"10.1016\/C2010-0-68399-4"},{"issue":"7","key":"1492_CR71","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/01.ALC.0000130804.08397.29","volume":"28","author":"HR Kranzler","year":"2004","unstructured":"Kranzler HR, Wesson DR, Billot L (2004) Naltrexone Depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 28(7):1051\u20131059. https:\/\/doi.org\/10.1097\/01.ALC.0000130804.08397.29","journal-title":"Alcohol Clin Exp Res"},{"issue":"9776","key":"1492_CR72","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","volume":"377","author":"E Krupitsky","year":"2011","unstructured":"Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL (2011) Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377(9776):1506\u20131513. https:\/\/doi.org\/10.1016\/S0140-6736(11)60358-9","journal-title":"Lancet"},{"issue":"11","key":"1492_CR73","first-page":"689","volume":"99","author":"JA Kulak","year":"2019","unstructured":"Kulak JA, Griswold KS (2019) Adolescent substance Use and Misuse: Recognition and Management. Am Family Phys 99(11):689\u2013696. https:\/\/pubmed.ncbi.nlm.nih.gov\/31150174\/","journal-title":"Am Family Phys"},{"issue":"2","key":"1492_CR74","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/bcp.12011","volume":"77","author":"N Kun\u00f8e","year":"2014","unstructured":"Kun\u00f8e N, Lobmaier P, Ngo H, Hulse G (2014) Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. Br J Clin Pharmacol 77(2):264\u2013271. https:\/\/doi.org\/10.1111\/bcp.12011","journal-title":"Br J Clin Pharmacol"},{"key":"1492_CR75","doi-asserted-by":"publisher","unstructured":"Lengyel M, K\u00e1llai-Szab\u00f3 N, Antal V, Laki AJ, Antal I (2019) Microparticles, microspheres, and microcapsules for advanced drug delivery. Sci Pharm 87:20.\u00a0https:\/\/doi.org\/10.3390\/SCIPHARM87030020","DOI":"10.3390\/SCIPHARM87030020"},{"key":"1492_CR76","doi-asserted-by":"crossref","unstructured":"Lev-Ran S, Balchand K, Lefebvre L, Araki KF, Le Foll B (2012) Pharmacotherapy of alcohol use disorders and concurrent psychiatric disorders: a review. Can J Psychiatry 57(6):342\u2013349","DOI":"10.1177\/070674371205700603"},{"key":"1492_CR77","unstructured":"Lewis DH (1990) Controlled release of bioactive agents from lactide\/glycolide polymers. In: Chasin M, Langer R (eds) Biodegradable polymers as drug delivery systems. Marcel Dekker, New York, pp 1\u201341"},{"key":"1492_CR78","doi-asserted-by":"publisher","unstructured":"Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Hajek P (2019) Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2019(2). https:\/\/doi.org\/10.1002\/14651858.CD003999.pub5","DOI":"10.1002\/14651858.CD003999.pub5"},{"issue":"2","key":"1492_CR79","doi-asserted-by":"publisher","first-page":"CD006140","DOI":"10.1002\/14651858.CD006140.pub2","volume":"16","author":"P Lobmaier","year":"2008","unstructured":"Lobmaier P, Kun\u00f8e Korn\u00f8rH, N., Bj\u00f8rndal A (2008) Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 16(2):CD006140. https:\/\/doi.org\/10.1002\/14651858.CD006140.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1492_CR80","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1755-5949.2010.00194.x","volume":"17","author":"P Lobmaier","year":"2014","unstructured":"Lobmaier P, Kun\u00f8e N, Gossop M, Waal H (2014) Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. Neurosci Ther 17(6):629\u2013636. https:\/\/doi.org\/10.1111\/j.1755-5949.2010.00194.x","journal-title":"Neurosci Ther"},{"key":"1492_CR81","doi-asserted-by":"publisher","unstructured":"Madan M, Bajaj A, Lewis S, Udupa N, Baig JA (2009) In Situ forming polymeric drug delivery systems. Indian J Pharm Sci 71(3):242\u2013251. https:\/\/doi.org\/10.4103\/0250-474X.56015","DOI":"10.4103\/0250-474X.56015"},{"issue":"6","key":"1492_CR82","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/0006-3223(87)90202-2","volume":"22","author":"R Malcolm","year":"1987","unstructured":"Malcolm R, O\u2019Neil PM, Von JM, Dickerson PC (1987) Naltrexone and dysphoria: a double-blind placebo-controlled trial. Biol Psychiatry 22(6):710\u2013716. https:\/\/doi.org\/10.1016\/0006-3223(87)90202-2","journal-title":"Biol Psychiatry"},{"key":"1492_CR83","doi-asserted-by":"publisher","unstructured":"Maldonado R, Calv\u00e9 P, Garc\u00eda-Blanco A, Domingo-Rodriguez L, Senabre E, Mart\u00edn-Garc\u00eda E (2021) Vulnerability to addiction. Neuropharmacology 186. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2021.108466","DOI":"10.1016\/J.NEUROPHARM.2021.108466"},{"key":"1492_CR84","doi-asserted-by":"publisher","unstructured":"Mason BJ, Heyser CJ (2010) Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 9(1):23\u201332. https:\/\/doi.org\/10.2174\/187152710790966641","DOI":"10.2174\/187152710790966641"},{"issue":"1","key":"1492_CR85","doi-asserted-by":"publisher","first-page":"07","DOI":"10.35946\/arcr.v41.1.07","volume":"41","author":"BJ Mason","year":"2021","unstructured":"Mason BJ, Heyser CJ (2021) Alcohol use disorder: the role of medication in recovery. Alcohol Res 41(1):07. https:\/\/doi.org\/10.35946\/arcr.v41.1.07","journal-title":"Alcohol Res"},{"key":"1492_CR86","doi-asserted-by":"publisher","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev\u00a03.\u00a0https:\/\/doi.org\/10.1002\/14651858.CD002209.PUB2\/INFORMATION\/EN","DOI":"10.1002\/14651858.CD002209.PUB2\/INFORMATION\/EN"},{"key":"1492_CR87","doi-asserted-by":"publisher","unstructured":"Michael T, Acampora KB, Joel C, Frank A, Bradley J, Jason O (2016) Viscoprene drug delivery system for the sustained release of disulfiram for treatment of alcohol use disorder. Front Bioeng Biotechnol\u00a04.\u00a0https:\/\/doi.org\/10.3389\/CONF.FBIOE.2016.01.02489\/EVENT_ABSTRACT","DOI":"10.3389\/CONF.FBIOE.2016.01.02489\/EVENT_ABSTRACT"},{"key":"1492_CR88","doi-asserted-by":"publisher","unstructured":"Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A (2011) Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 1. https:\/\/doi.org\/10.1002\/14651858.CD001333.PUB2","DOI":"10.1002\/14651858.CD001333.PUB2"},{"issue":"11","key":"1492_CR89","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s002280000223","volume":"56","author":"L Molander","year":"2001","unstructured":"Molander L, Lunell E (2001) Pharmacokinetic investigation of a nicotine sublingual tablet. Eur J Clin Pharmacol 56(11):813\u2013819. https:\/\/doi.org\/10.1007\/s002280000223","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"1492_CR90","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3018(19)30147-X","volume":"6","author":"S Nachman","year":"2019","unstructured":"Nachman S, Townsend CL, Abrams EL, Capparelli E, Clayden P, Lockman S, Jean-Philippe P, Mayer K, Mirochnick M, McKenzie-White J, Struble K, Watts H, Flexner C (2019) Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant women: knowledge gaps and research priorities. Lancet HIV 6(8):e552\u2013558. https:\/\/doi.org\/10.1016\/S2352-3018(19)30147-X","journal-title":"Lancet HIV"},{"key":"1492_CR91","doi-asserted-by":"crossref","unstructured":"Nagano T, Katsurada M, Yasuda Y, Kobayashi K, Nishimura Y (2019) Current pharmacological treatments for smoking cessation and new agents undergoing clinical trials. Ther Adv Respir Dis\u00a013:1753466619875925. https:\/\/doi.org\/10.1177\/1753466619875925","DOI":"10.1177\/1753466619875925"},{"issue":"1","key":"1492_CR92","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/J.TINS.2008.09.009","volume":"32","author":"NH Naqvi","year":"2009","unstructured":"Naqvi NH, Bechara A (2009) The hidden island of addiction: the insula. Trends Neurosci 32(1):56\u201367. https:\/\/doi.org\/10.1016\/J.TINS.2008.09.009","journal-title":"Trends Neurosci"},{"issue":"5811","key":"1492_CR93","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1126\/SCIENCE.1135926","volume":"315","author":"NH Naqvi","year":"2007","unstructured":"Naqvi NH, Rudrauf D, Damasio H, Bechara A (2007) Damage to the insula disrupts addiction to cigarette smoking. Sci (New York N Y) 315(5811):531\u2013534. https:\/\/doi.org\/10.1126\/SCIENCE.1135926","journal-title":"Sci (New York N Y)"},{"key":"1492_CR94","unstructured":"National Institutes of Health (2022) E-cigarette use may lead some to quit traditional cigarettes. https:\/\/www.nih.gov\/news-events\/nih-research-matters\/e-cigarette-use-may-lead-some-quit-traditional-cigarettes. Accessed 12 Aug 2022"},{"key":"1492_CR95","unstructured":"National Institute on Alcohol Abuse and\u00a0Alcoholism\u00a0(2023) Economic burden of alcohol misuse in the United States. https:\/\/nih.gov\/alcohols-effects-health\/alcohol-topics\/alcohol-facts-and-statistics\/economic-burden-alcohol-misuse-united-states. Accessed 29 Sept 2024"},{"key":"1492_CR96","unstructured":"National Tobacco Control Programme (2024) Retrieved from https:\/\/mnhm.uk.gov.in\/pages\/display\/99-national-tobacco-control-programme. Accessed 29 Sept"},{"key":"1492_CR97","doi-asserted-by":"publisher","unstructured":"Negrin CM, Delgado A, Llabr\u00e9s M, Evora C (2001) In vivo-in vitro study of biodegradable methadone delivery systems. Biomaterials 22(6):563\u2013570. https:\/\/doi.org\/10.1016\/s0142-9612(00)00214-3","DOI":"10.1016\/s0142-9612(00)00214-3"},{"key":"1492_CR98","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jconrel.2003.12.008","volume":"95","author":"CM Negr\u00edn","year":"2004","unstructured":"Negr\u00edn CM, Delgado A, Llabre\u00b4s M, E\u00b4 vora C (2004) Methadone implants for methadone maintenance treatment. In vitro and in vivo animal studies. J Controlled Release 95:413\u2013421","journal-title":"J Controlled Release"},{"issue":"4","key":"1492_CR99","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/07347324.2017.1361763","volume":"35","author":"J Nelson","year":"2017","unstructured":"Nelson J, Bundoc-Baronia R, Comiskey G, McGovern TF (2017) Facing addiction in America: the Surgeon General\u2019s report on Alcohol, drugs, and Health: a Commentary. Alcoholism Treat Q 35(4):445\u2013454. https:\/\/doi.org\/10.1080\/07347324.2017.1361763","journal-title":"Alcoholism Treat Q"},{"key":"1492_CR100","unstructured":"NIDA (2021) December 2. Overview. Retrieved from https:\/\/nida.nih.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/overview. Accessed 6 Oct 2023"},{"key":"1492_CR101","unstructured":"NIDA (2022) Retrieved from https:\/\/nida.nih.gov\/publications\/research-reports\/tobacco-nicotine-and-e-cigarettes. Accessed 10 Oct 2023"},{"issue":"3","key":"1492_CR102","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/ADM.0000000000000125","volume":"9","author":"EV Nunes","year":"2015","unstructured":"Nunes EV, Krupitsky E, Ling W, Zummo J, Memisoglu A, Silverman BL, Gastfriend DR (2015) Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): who will respond? J Addict Med 9(3):238\u2013243. https:\/\/doi.org\/10.1097\/ADM.0000000000000125","journal-title":"J Addict Med"},{"key":"1492_CR103","doi-asserted-by":"publisher","unstructured":"Ohia-Nwoko O, Kosten TA, Haile CN (2016) Animal models and the development of vaccines to treat substance use disorders. Int Rev Neurobiol 126:263\u201391.\u00a0https:\/\/doi.org\/10.1016\/bs.irn.2016.02.009","DOI":"10.1016\/bs.irn.2016.02.009"},{"issue":"4","key":"1492_CR104","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/10837450.2013.784334","volume":"19","author":"KP Pagar","year":"2013","unstructured":"Pagar KP, Vavia PR (2013) Naltrexone-loaded poly[La\u2013(Glc\u2013Leu)] polymeric microspheres for the treatment of alcohol dependence: in vitro characterization and in vivo biocompatibility assessment. Pharm Dev Technol 19(4):385\u2013394. https:\/\/doi.org\/10.3109\/10837450.2013.784334","journal-title":"Pharm Dev Technol"},{"issue":"1","key":"1492_CR105","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/J.PHYSBEH.2011.04.063","volume":"104","author":"SL Parylak","year":"2011","unstructured":"Parylak SL, Koob GF, Zorrilla EP (2011) The dark side of food addiction. Physiol Behav 104(1):149\u2013156. https:\/\/doi.org\/10.1016\/J.PHYSBEH.2011.04.063","journal-title":"Physiol Behav"},{"key":"1492_CR106","doi-asserted-by":"publisher","unstructured":"Pascoli V, Hiver A, Van Zessen R, Loureiro M, Achargui R, Harada M, Flakowski J, L\u00fcscher C (2018) Stochastic synaptic plasticity underlying compulsion in a model of addiction. Nat 2018 564(7736):366\u2013371. https:\/\/doi.org\/10.1038\/s41586-018-0789-4","DOI":"10.1038\/s41586-018-0789-4"},{"key":"1492_CR107","doi-asserted-by":"publisher","unstructured":"Patel RB, Solorio L, Wu H, Krupka T, Exner AA (2010) Effect of injection site on in situ implant formation and drug release in vivo. J Control Release 147(3):350\u2013358. https:\/\/doi.org\/10.1016\/j.jconrel.2010.08.020","DOI":"10.1016\/j.jconrel.2010.08.020"},{"key":"1492_CR108","doi-asserted-by":"publisher","unstructured":"Peacock A, Leung J, Larney S et al (2018) Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Glob Stat Addict 113(10):1905\u20131926. https:\/\/doi.org\/10.1111\/add.14234","DOI":"10.1111\/add.14234"},{"issue":"2","key":"1492_CR109","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/J.BRAINRESREV.2010.09.001","volume":"65","author":"JL Perry","year":"2011","unstructured":"Perry JL, Joseph JE, Jiang Y, Zimmerman RS, Kelly TH, Darna M, Huettl P, Dwoskin LP, Bardo MT (2011) Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions. Brain Res Rev 65(2):124. https:\/\/doi.org\/10.1016\/J.BRAINRESREV.2010.09.001","journal-title":"Brain Res Rev"},{"key":"1492_CR110","doi-asserted-by":"publisher","unstructured":"Phillips M (1987) Persistent sensitivity to ethanol following a single dose of parenteral sustained-release disulfiram. Adv Alcohol Subst Abuse 151\u201361. https:\/\/doi.org\/10.1300\/J251V07N01_05","DOI":"10.1300\/J251V07N01_05"},{"issue":"12","key":"1492_CR111","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1002\/JPS.2600731214","volume":"73","author":"M Phillips","year":"1984","unstructured":"Phillips M, Gresser JD (1984) Sustained-release characteristics of a new implantable formulation of disulfiram. J Pharm Sci 73(12):1718\u20131720. https:\/\/doi.org\/10.1002\/JPS.2600731214","journal-title":"J Pharm Sci"},{"issue":"5","key":"1492_CR112","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1530-0277.1992.tb01901.x","volume":"16","author":"M Phillips","year":"1992","unstructured":"Phillips M, Greenberg J (1992) Dose-ranging study of depot disulfiram in alcohol abusers. Alcohol Clin Exp Res 16(5):964\u2013967. https:\/\/doi.org\/10.1111\/j.1530-0277.1992.tb01901.x","journal-title":"Alcohol Clin Exp Res"},{"key":"1492_CR113","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/J.MEMSCI.2012.04.017","volume":"411\u2013412","author":"W Pichayakorn","year":"2012","unstructured":"Pichayakorn W, Suksaeree J, Boonme P, Amnuaikit T, Taweepreda W, Ritthidej GC (2012) Nicotine transdermal patches using polymeric natural rubber as the matrix controlling system: Effect of Polymer and plasticizer blends. J Membr Sci 411\u2013412:81\u201390. https:\/\/doi.org\/10.1016\/J.MEMSCI.2012.04.017","journal-title":"J Membr Sci"},{"issue":"8","key":"1492_CR114","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1081\/DDC-120024180","volume":"29","author":"T Pongjanyakul","year":"2003","unstructured":"Pongjanyakul T, Prakongpan S, Priprem A (2003) Acrylic matrix type nicotine transdermal patches: in vitro evaluations and batch-to-batch uniformity. Drug Dev Ind Pharm 29(8):843\u2013853. https:\/\/doi.org\/10.1081\/DDC-120024180","journal-title":"Drug Dev Ind Pharm"},{"key":"1492_CR115","doi-asserted-by":"publisher","unstructured":"Porras-Gomez M, reviews CL-L, crystals (2019) & undefined. (2019). Lipid-based liquid crystalline films and solutions for the delivery of cargo to cells. Taylor & Francis\u00a07(2):167\u2013182. https:\/\/doi.org\/10.1080\/21680396.2019.1666752","DOI":"10.1080\/21680396.2019.1666752"},{"key":"1492_CR116","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/archinte.158.18.2035","volume":"158","author":"AV Prochazka","year":"1998","unstructured":"Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D (1998) A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 158:2035\u20132039","journal-title":"Arch Intern Med"},{"key":"1492_CR117","doi-asserted-by":"crossref","unstructured":"Raleigh MD, Pravetoni M, Harris AC, Birnbaum AK, Pentel PR (2013) Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther 344:397\u2013406","DOI":"10.1124\/jpet.112.201194"},{"key":"1492_CR118","doi-asserted-by":"publisher","unstructured":"Raleigh M, Pentel PR, LeSage MG (2014) Pharmacokinetic correlates of the effects of a Heroin Vaccine on Heroin Self-Administration in rats. PLoS One 9(12):e115696 https:\/\/doi.org\/10.1371\/journal.pone.0115696","DOI":"10.1371\/journal.pone.0115696"},{"key":"1492_CR119","unstructured":"Ratnaparkhi M, Jyoti P (2013) Sustained release oral drug delivery system - an overview.\u00a0Int J Pharm Sci Res Rev 2(3):11\u201321"},{"issue":"1","key":"1492_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1747-597X-2-35","volume":"2","author":"AS Reece","year":"2007","unstructured":"Reece AS (2007) Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse: Treat Prev Policy 2(1):1\u201315. https:\/\/doi.org\/10.1186\/1747-597X-2-35","journal-title":"Subst Abuse: Treat Prev Policy"},{"issue":"2","key":"1492_CR121","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/J.BANDC.2004.09.016","volume":"56","author":"KR Ridderinkhof","year":"2004","unstructured":"Ridderinkhof KR, Van Den Wildenberg WPM, Segalowitz SJ, Carter CS (2004) Neurocognitive mechanisms of cognitive control: the role of prefrontal cortex in action selection, response inhibition, performance monitoring, and reward-based learning. Brain Cogn 56(2):129\u2013140. https:\/\/doi.org\/10.1016\/J.BANDC.2004.09.016","journal-title":"Brain Cogn"},{"issue":"5","key":"1492_CR122","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/J.EURONEURO.2005.11.001","volume":"16","author":"HG Roozen","year":"2006","unstructured":"Roozen HG, de Waart R, van der Windt DAWM, van den Brink W, de Jong CAJ, Kerkhof AJFM (2006) A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacol 16(5):311\u2013323. https:\/\/doi.org\/10.1016\/J.EURONEURO.2005.11.001","journal-title":"Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacol"},{"issue":"2","key":"1492_CR123","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1176\/appi.focus.20180043","volume":"17","author":"RN Rosenthal","year":"2019","unstructured":"Rosenthal RN (2019) Novel formulations of Buprenorphine for Treatment of Opioid Use Disorder. Focus 17(2):104\u2013109. https:\/\/doi.org\/10.1176\/appi.focus.20180043","journal-title":"Focus"},{"key":"1492_CR124","doi-asserted-by":"publisher","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (2010) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev\u00a012. https:\/\/doi.org\/10.1002\/14651858.CD001867.PUB3","DOI":"10.1002\/14651858.CD001867.PUB3"},{"key":"1492_CR125","unstructured":"Royal Free London NHS Foundation Trust (2023) Nicotine inhaler. https:\/\/www.royalfree.nhs.uk\/patients-visitors\/stop-smoking\/treatment-to-help-you-stop-smoking\/nicotine-replacement-therapy\/nicotine-inhalator\/. October 6"},{"issue":"5","key":"1492_CR126","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.amepre.2015.05.031","volume":"49","author":"JJ Sacks","year":"2010","unstructured":"Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD (2010) National and state costs of excessive alcohol consumption. Am J Prev Med 49(5):e73\u2013e79","journal-title":"Am J Prev Med"},{"key":"1492_CR127","unstructured":"SAMHSA (2015) Medication for the treatment of alcohol use disorder: a brief guide. https:\/\/store.samhsa.gov.\u00a0Accessed 28 Oct 2024"},{"key":"1492_CR128","unstructured":"SAMHSA (2022) Treatment approaches for drug addiction drugfacts. https:\/\/www.samhsa.gov.\u00a0Accessed 26 Oct 2024"},{"issue":"1","key":"1492_CR129","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/00003088-199631010-00005","volume":"31","author":"NG Schneider","year":"1996","unstructured":"Schneider NG, Lunell E, Olmstead RE, Fagerstr\u00f6m KO (1996) Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet 31(1):65\u201380. https:\/\/doi.org\/10.2165\/00003088-199631010-00005","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1492_CR130","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJMra1604339","volume":"375","author":"MA Schuckit","year":"2016","unstructured":"Schuckit MA (2016) Treatment of Opioid-Use disorders. N Engl J Med 375(4):357\u2013368. https:\/\/doi.org\/10.1056\/NEJMra1604339","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"1492_CR131","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/J.IJPHARM.2015.11.029","volume":"497","author":"M Shergill","year":"2016","unstructured":"Shergill M, Patel M, Khan S, Bashir A, McConville C (2016) Development and characterisation of sustained release solid dispersion oral tablets containing the poorly water soluble drug disulfiram. Int J Pharm 497(1\u20132):3\u201311. https:\/\/doi.org\/10.1016\/J.IJPHARM.2015.11.029","journal-title":"Int J Pharm"},{"issue":"5","key":"1492_CR132","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1046\/J.1360-0443.2002.00141.X","volume":"97","author":"S Shiffman","year":"2002","unstructured":"Shiffman S, Rolf CN, Hellebusch SJ, Gorsline J, Gorodetzky CW, Chiang YK, Schleusener DS, Di Marino ME (2002) Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction (Abingdon England) 97(5):505\u2013516. https:\/\/doi.org\/10.1046\/J.1360-0443.2002.00141.X","journal-title":"Addiction (Abingdon England)"},{"key":"1492_CR133","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0169-409X(97)00048-3","volume":"28","author":"MS Shive","year":"1997","unstructured":"Shive MS, Anderson JM (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5\u201324","journal-title":"Adv Drug Deliv Rev"},{"issue":"8890","key":"1492_CR134","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s0140-6736(94)90933-4","volume":"343","author":"C Silagy","year":"1994","unstructured":"Silagy C, Mant D, Fowler G, Lodge M (1994) Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet (London England) 343(8890):139\u2013142. https:\/\/doi.org\/10.1016\/s0140-6736(94)90933-4","journal-title":"Lancet (London England)"},{"key":"1492_CR135","doi-asserted-by":"publisher","unstructured":"Sinclair JD (2001) Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 36(1):2\u201310. https:\/\/doi.org\/10.1093\/alcalc\/36.1.2","DOI":"10.1093\/alcalc\/36.1.2"},{"issue":"4","key":"1492_CR136","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1365-2753.2011.01662.x","volume":"18","author":"R Sirriyeh","year":"2012","unstructured":"Sirriyeh R, Lawton R, Gardner P, Armitage G (2012) Reviewing studies with diverse designs: the development and evaluation of a new tool. J Eval Clin Pract 18(4):746\u2013752. https:\/\/doi.org\/10.1111\/j.1365-2753.2011.01662.x","journal-title":"J Eval Clin Pract"},{"key":"1492_CR137","doi-asserted-by":"crossref","unstructured":"Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295(1):321-7","DOI":"10.1016\/S0022-3565(24)38905-0"},{"key":"1492_CR138","unstructured":"Soltani H, Pardakhty A (2016) Marketed new drug delivery systems for opioid agonists\/antagonists administration: a rapid overview. Addict Health 8(2):115\u2013122"},{"issue":"7","key":"1492_CR139","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/cap.2019.0009","volume":"29","author":"LM Squeglia","year":"2019","unstructured":"Squeglia LM, Fadus MC, McClure EA, Tomko RL, Gray KM (2019) Pharmacological treatment of Youth Substance Use disorders. J Child Adolesc Psychopharmacol 29(7):559\u2013572. https:\/\/doi.org\/10.1089\/cap.2019.0009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1492_CR140","unstructured":"Stokes M, Patel P, Abdijadid S (2022) Disulfiram. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"issue":"3","key":"1492_CR141","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/01.JCP.0000222512.25649.08","volume":"26","author":"JJ Suh","year":"2006","unstructured":"Suh JJ, Pettinati HM, Kampman KM, O\u2019Brien CP (2006) The status of disulfiram: a half of a century later. J Clin Psychopharmacol 26(3):290\u2013302. https:\/\/doi.org\/10.1097\/01.JCP.0000222512.25649.08","journal-title":"J Clin Psychopharmacol"},{"key":"1492_CR142","doi-asserted-by":"publisher","unstructured":"Syed YY, Keating GM (2013) Extended-release intramuscular naltrexone (VIVITROL\u00ae): a review of its use in the Prevention of Relapse to opioid dependence in detoxified patients. CNS Drugs 2013 27:10(10):851\u2013861. https:\/\/doi.org\/10.1007\/S40263-013-0110-X","DOI":"10.1007\/S40263-013-0110-X"},{"issue":"6","key":"1492_CR143","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ntr\/ntp058","volume":"11","author":"TO Tevyaw","year":"2009","unstructured":"Tevyaw TO, Colby SM, Tidey JW, Kahler CW, Rohsenow DJ, Barnett NP, Gwaltney CJ, Monti PM (2009) Contingency management and motivational enhancement: a randomized clinical trial for college student smokers. Nicotine Tob Res 11(6):739\u2013749. https:\/\/doi.org\/10.1093\/ntr\/ntp058","journal-title":"Nicotine Tob Res"},{"key":"1492_CR144","doi-asserted-by":"publisher","unstructured":"Thavorncharoensap M, Teerawattananon Y, Yothasamut J, Lertpitakpong C, Chaikledkaew U (2009) The economic impact of alcohol consumption: a systematic review. Subst Abuse Treat Prev Policy\u00a04.\u00a0https:\/\/doi.org\/10.1186\/1747-597X-4-20","DOI":"10.1186\/1747-597X-4-20"},{"key":"1492_CR145","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.jconrel.2022.06.034","volume":"348","author":"AO Tijani","year":"2022","unstructured":"Tijani AO, Garg J, Frempong D, Verana G, Kaur J, Joga R, Sabanis CD, Kumar S, Kumar N, Puri A (2022) Sustained drug delivery strategies for treatment of common substance use disorders: promises and challenges. J Controlled Release (Vol 348:970\u20131003. https:\/\/doi.org\/10.1016\/j.jconrel.2022.06.034. Elsevier B.V","journal-title":"J Controlled Release (Vol"},{"issue":"6","key":"1492_CR146","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3109\/10717544.2015.1025314","volume":"23","author":"J Varshosaz","year":"2016","unstructured":"Varshosaz J, Minaiyan M, Zaki MR, Fathi M, Jaleh H (2016) In vitro\/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl. Drug Delivery 23(6):1948\u20131954. https:\/\/doi.org\/10.3109\/10717544.2015.1025314","journal-title":"Drug Delivery"},{"issue":"2","key":"1492_CR147","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/BJP.2008.30","volume":"154","author":"V Vengeliene","year":"2008","unstructured":"Vengeliene V, Bilbao A, Molander A, Spanagel R (2008) Neuropharmacology of alcohol addiction. Br J Pharmacol 154(2):299\u2013315. https:\/\/doi.org\/10.1038\/BJP.2008.30","journal-title":"Br J Pharmacol"},{"key":"1492_CR148","doi-asserted-by":"publisher","unstructured":"Verdejo-Garc\u00eda A, Bechara A (2009) A somatic marker theory of addiction. Neuropharmacology\u00a056(SUPPL. 1):48\u201362. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2008.07.035","DOI":"10.1016\/J.NEUROPHARM.2008.07.035"},{"issue":"8","key":"1492_CR149","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/J.NEUBIOREV.2012.05.007","volume":"36","author":"A Verdejo-Garcia","year":"2012","unstructured":"Verdejo-Garcia A, Clark L, Dunn BD (2012) The role of interoception in addiction: a critical review. Neurosci Biobehav Rev 36(8):1857\u20131869. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2012.05.007","journal-title":"Neurosci Biobehav Rev"},{"key":"1492_CR150","unstructured":"Vivitrol\u00ae for Alcohol Dependence and Opioid Dependence (2024).\u00a0https:\/\/www.vivitrol.com. Accessed 30 Sept"},{"issue":"4","key":"1492_CR151","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2217\/14796708.1.4.389","volume":"1","author":"JR Volpicelli","year":"2006","unstructured":"Volpicelli JR, Fenton M (2006) Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurol 1(4):389\u2013398. https:\/\/doi.org\/10.2217\/14796708.1.4.389","journal-title":"Future Neurol"},{"issue":"3","key":"1492_CR152","doi-asserted-by":"publisher","first-page":"425","DOI":"10.12816\/0048737","volume":"10","author":"U Wadgave","year":"2016","unstructured":"Wadgave U, Nagesh L (2016) Nicotine replacement therapy: an overview. Int J Health Sci 10(3):425\u2013435. https:\/\/doi.org\/10.12816\/0048737","journal-title":"Int J Health Sci"},{"key":"1492_CR153","doi-asserted-by":"publisher","unstructured":"Wilkes S (2008) The use of bupropion SR in cigarette smoking cessation. Int\u00a0J Chronic Obstruct Pulmon Dis 3(1):45\u201353. https:\/\/doi.org\/10.2147\/copd.s1121","DOI":"10.2147\/copd.s1121"},{"issue":"1","key":"1492_CR154","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1196\/ANNALS.1401.024","volume":"1121","author":"CA Winstanley","year":"2007","unstructured":"Winstanley CA (2007) The Orbitofrontal Cortex, Impulsivity, and addiction. Ann N Y Acad Sci 1121(1):639\u2013655. https:\/\/doi.org\/10.1196\/ANNALS.1401.024","journal-title":"Ann N Y Acad Sci"},{"key":"1492_CR155","doi-asserted-by":"publisher","unstructured":"Xie X, Lin W, Xing C et al (2015) In Vitro and In Vivo evaluations of PLGA microspheres containing nalmefene. PLoS One 10(5). https:\/\/doi.org\/10.1371\/journal.pone.0125953-","DOI":"10.1371\/journal.pone.0125953-"},{"issue":"4","key":"1492_CR156","doi-asserted-by":"publisher","first-page":"e059672","DOI":"10.1136\/bmjopen-2021-059672","volume":"12","author":"S Zimmermann","year":"2022","unstructured":"Zimmermann S, Thomas BC, Krisam J, Limprecht R, Klose C, Stenger M, Pourbaix M, Ries M, Vollstaedt-Klein S, Koopmann A, Lenz B, Kiefer F, Bach P (2022) ON-ICE trial: investigation of the combined effects of oxytocin and naltrexone on stress-induced and alcohol cue-induced craving in alcohol use disorder-study protocol of a phase II randomised double-blind placebo-controlled parallel-group trial. BMJ open 12(4):e059672. https:\/\/doi.org\/10.1136\/bmjopen-2021-059672","journal-title":"BMJ open"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-024-01492-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-024-01492-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-024-01492-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:55:35Z","timestamp":1740549335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-024-01492-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":156,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["1492"],"URL":"https:\/\/doi.org\/10.1007\/s11011-024-01492-8","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"19 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}